Open Drug Discovery Center for Alzheimer's Disease

开放药物发现中心AD（Open-AD）管理和数据管理核心（管理和 数据核心）有三个功能：（1）提供全面的行政组织、监督和管理 对于Open-AD内执行的所有工作，（2）管理与外部AD调查人员的沟通， 社区，包括目标优先级，以及（3）支持所有Open-AD生成的开放分发 供独立研究者使用的试剂、工具、探针、数据和知识。管理和数据核心 将建立和实施行政和管理结构，以确保中心适当 会议里程碑和交付成果，征求意见，并在整个社区公开分享资产， 跨核心工作，以便在目标计划通过时对其进行有效评估和管理， 中间管道。此外，管理核心将管理开放广告与外部研究的互动 社区，以征求和评估一套社区优先的目标，在一个多样化的投资组合， 治疗假设，以确定领域专家，可以作为顾问和合作伙伴，以指导决策 围绕每一个选定的治疗假设，并确定将使用这些资产的研究人员 由该中心开发，以测试这些（和其他）治疗假设。与外部研究的互动 社区将通过Open-AD AD专家小组、外部咨询委员会、 开放式广告会议、针对特定目标的研讨会，以及通过Agora平台（以前称为AMP-AD Wall ，agora.ampadportal.org）。为了邀请整个AD研究社区参与我们的 新目标的调查，拟议的开放广告中心将采取一种完全开放的方法来瞄准 验证和药物发现。所有Open-AD研究者已同意将所有数据、知识、试剂， 和工具，包括化学和生物探针进入开放领域，没有知识产权要求。到 支持广泛分发并鼓励重复使用，Open-AD将捐赠分发任何试剂的权利， 商业供应商，非独家，无报酬。所有中心活动将在 使用Open-AD协作工作区打开。为每个人开发的所有资源、数据和知识 治疗方法将使用标准资源（cDNA克隆的AddGene，ThermoFisher 抗体等）-所有信息将通过Agora平台进行汇总和注册。

The Open Drug Discovery Center for AD (Open-AD) Administrative and Data Management Core (Admin and Data Core) serves three functions: (1) to provide overall administrative organization, oversight and management for all work performed within the Open-AD, (2) to manage communications with external AD investigators across the community including for target prioritization, and (3) to support the open distribution of all Open-AD generated reagents, tools, probes, data, and knowledge for use by independent investigators. The Admin and Data Core will establish and implement administrative and management structures to ensure that the Center is appropriately meeting milestones and deliverables, is soliciting input and openly sharing assets across the community, and is working across Cores for effective evaluation and management of target programs as they move through the Center pipeline. In addition, the Admin Core will manage Open-AD interactions with the external research community so as to solicit and evaluate a community-prioritized set of targets across a diverse portfolio of therapeutic hypotheses, to identify domain experts that can serve as advisors and partners to guide decisions around each therapeutic hypothesis that is selected, and to identify researchers that will use the assets developed by the Center to test these (and other) therapeutic hypotheses. Interactions with the external research community will be performed through the Open-AD AD expert panel, the External Advisory Board, an annual Open-AD meeting, target-specific workshops, and through the Agora platform (formerly called the AMP-AD Wall of Targets, agora.ampadportal.org). In order to invite the entire AD research community to participate in our investigation of novel targets, the proposed Open-AD Center will adopt a radically open approach to target validation and drug discovery. All Open-AD investigators have agreed to place all data, knowledge, reagents, and tools including chemical and biological probes into the open domain with no intellectual property claims. To support wide distribution and encourage reuse, Open-AD will donate the rights to distribute any reagent to commercial suppliers, non-exclusively and for no compensation. All Center activities will be performed in the open using the Open-AD collaboration workspace. All resources, data, and knowledge developed for each therapeutic approach will be disseminated using standard resource (AddGene for cDNA clones, Thermo Fisher for antibodies, etc) – and all information will be summarized and registered through the Agora platform.